There are currently 40 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Carcinoma, Non-Small-Cell Lung participants are California, Texas, Florida and New York.
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968
Recruiting
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Infirmary Cancer Care ( Site 0418), Mobile, Alabama +165 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Southern Cancer Center, PC, Daphne, Alabama +16 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Development and Analysis of a Stool Bank for Cancer Patients
NCT04291755
Recruiting
This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are limited due to differences between mouse and human physiology and immunology, as well as the inherent differences in gut microbial populations between the two m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Compassionate Care Research Group, Inc., Fountain Valley, California +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Register for Updates
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
NCT00100256
Recruiting
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are no bad side effects, then increasing the dose when we are confident that it is safe to do so.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/31/2022
Locations: Not set, Iowa City, Iowa +1 locations
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
Register for Updates